AVX 0.00% 2.5¢ avexa limited

dronas unanimous decisions!, page-5

  1. 1,098 Posts.
    Lots of guesses here... and as far as board plots are concerned, guessing what happened is the only thing we can do, so it is not really constructive.

    All of us are disappointed, pissed off and broke - that's a fact. Got in over 3 years ago, at 72c.

    Why ? this is a risky game, and we missed the boat in many areas.
    1- I guess the product was not as good as we were lead to believe. We should have known. If they had nailed the product - not so much scientifically, but commercially, why would these big pharmas wait for the end of the process whilst most deals take place much earlier ?
    And this, to me, goes directly into JC's territory. It seems he completely missed the point. Head in the sand, trying to produce the safest product without worrying about key commercial/practical things.
    2- Then the M&A side ended up as a complete failure.

    So now, where do we go from there... the next immediate step is this regional deal. Hard to figure out what the likelihood of this happening is. Even harder to work out how big / small this would be. Or this CDZ mob - not sure what they are after ? cash seems to be the most obvious driver. It can't be the product, staff or IP.

    Who to take us there ? Drona ? if possible, no. The other candidates ? not for the moment. I can't understand why they don't disclose their plan - if they have one. Because they don't want to provide Drona with ammunition ? rubbish. They should worry about the shareholders, not Drona, and let us know what they plan to do. If not, I will not vote for them. That said, in 5 weeks, we should know what will happen with the regional deal, and if it is going south then I would expect Drona to throw the towel and go. Easy choice then.
    Too long posting, sorry.... grumble, grumble, grumble...
 
watchlist Created with Sketch. Add AVX (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.